Section Arrow
Quote
AUTL.NASDAQ
- Autolus Therapeutics plc
Quotes are at least 15-min delayed:2026/05/24 13:50 EDT
Regular Hours
Last
 1.7
+0.05 (+3.03%)
Day High 
1.75 
Prev. Close
1.65 
1-M High
1.95 
Volume 
1.04M 
Bid
1.7
Ask
1.74
Day Low
1.6646 
Open
1.67 
1-M Low
1.39 
Market Cap 
439.14M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.64 
20-SMA 1.58 
50-SMA 1.5 
52-W High 2.7 
52-W Low 1.175 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.09/-0.67
Enterprise Value
505.96M
Balance Sheet
Book Value Per Share
0.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
75.39M
Operating Revenue Per Share
0.02
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.